|
1 Company |
|
1 Product |
|
1 Product |
|
0 Mechanisms of Action |
|
0 Trials |
|
6 News |
|
- glycosylated recombinant human interleukin-7 (CYT107) / Revimmune
Trial termination, Lymphopenia: Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE) (clinicaltrials.gov) - Sep 8, 2014
P1/2, N=21, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Completed --> Terminated; Bankruptcy of Drug manufacturer: Drug not available
- glycosylated recombinant human interleukin-7 (CYT107) / Revimmune
Trial primary completion date, Lymphopenia: Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE) (clinicaltrials.gov) - May 28, 2014
P1/2, N=21, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Completed --> Terminated; Bankruptcy of Drug manufacturer: Drug not available Trial primary completion date: Dec 2014 --> May 2014
- glycosylated recombinant human interleukin-7 (CYT107) / Revimmune
Trial completion date, Lymphopenia: Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE) (clinicaltrials.gov) - May 28, 2014
P1/2, N=21, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Dec 2014 --> May 2014 Trial completion date: Dec 2014 --> May 2014
- glycosylated recombinant human interleukin-7 (CYT107) / Revimmune
Trial completion, Lymphopenia: Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE) (clinicaltrials.gov) - May 28, 2014
P1/2, N=21, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Dec 2014 --> May 2014 Active, not recruiting --> Completed
- glycosylated recombinant human interleukin-7 (CYT107) / Revimmune
Enrollment change, Lymphopenia: Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE) (clinicaltrials.gov) - Jul 8, 2013
P1/2, N=21, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed N=15 --> 21
- glycosylated recombinant human interleukin-7 (CYT107) / Revimmune
Enrollment closed, Lymphopenia: Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE) (clinicaltrials.gov) - Jun 18, 2013
P1/2, N=21, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=15 --> 21 Recruiting --> Active, not recruiting